Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis

Journal of the National Cancer Institute

Volumn 99, Issue 13, 2007, Pages 1016-1024

  Wilkinson, Gregg S ^a,b   Kuo, Yong Fang ^a,b   Freeman, Jean L ^a,b   Goodwin, James S ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; PAMIDRONIC ACID; STEROID; ZOLEDRONIC ACID;

AGED; ALCOHOLISM; ARTICLE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER CLASSIFICATION; CIGARETTE SMOKING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG DOSE INCREASE; FACE SURGERY; FEMALE; GEOGRAPHIC DISTRIBUTION; HAZARD RATIO; HUMAN; HYPERLIPIDEMIA; JAW DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; OBESITY; ORTHOPEDIC SURGERY; OSTEOMYELITIS; PANCREATITIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; BONE; CANCER REGISTRY; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; INFLAMMATION; MEDICARE; MIDDLE AGED; NEOPLASM; PATHOLOGY; UNITED STATES;

AGED; AGED, 80 AND OVER; BONE AND BONES; DIPHOSPHONATES; FEMALE; HUMANS; INFLAMMATION; JAW DISEASES; MALE; MEDICARE; MIDDLE AGED; NEOPLASMS; OSTEONECROSIS; SEER PROGRAM; UNITED STATES;

EID: 34447252128     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm025     Document Type: Article

References (35)

1. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
2. U.S. Food and Drug Administration. Label and approval history, AREDIA, NDA no. 020035. Available at: http://www.accessdata.fda.gov/. [Last accessed: June 9, 2006.]
3. U.S. Food and Drug Administration. Label and approval history, ZOMETA, NDA no. 021223. Available at: http://www.accessdata.fda.gov/. [Last accessed: April 26,2006.]
4. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
5. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12.
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61:1115.
7. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone osteonecrosis/osteoporosis of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63: 1567-75.
8. Ruggiero SL, Mebrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
9. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.
10. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
11. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006; 116:115-20.
12. Tarassoff P, Csermak K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients [letter]. J Oral Maxillofac Surg 2003;61:1238-9.
13. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
14. Bone HG, Santora AC. Ten years of alendronate treatment for osteoporosis in postmenopausal women [letter]. N Engl J Med 2004;351:191-2; author reply.
15. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-7.
16. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71.
17. Zervas K, Verrou E, Teleioudis E, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 pa tients. Br J Haematol 2006;134:620-3.
18. Walter C, Groetz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15:197-202.
19. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353;1:99-100.
20. Rubin R. Drug linked to death of jawbone. USA Today, 2005 March 13. Available at: http://www.usatoday.com/news/health/ 2005-03-13-jawbone-deaths_x.htm. [Last accessed: June 3, 2007.]
21. Kolata G. Drug for bones is newly linked to jaw disease. New York Times, 2006 June 2. Available at: http://www.nytimes.com/2006/06/02/health/ 02jaw.html. [Last accessed: June 3, 2007.]
22. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy aw): Is this the phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9.
23. Cheng A, Mavrokokki A, Carter G, Stein B, Fazzalari NL, Wilson DF, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50 (Suppl 2):S4-13.
24. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-42.
25. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Population-based analysis of fracture risk after androgen deprivation therapy for prostate cancer. N Engl J Med 2005;352:154-64.
26. Department of Health and Human Services, National Institutes for Health, National Cancer Institute NCI. SEER-Medicare linked database. Available at: http://healthservices.cancer.gov/seermedicare. [Last accessed: October 24, 2006.]
27. Jones JP Jr. Osteonecrosis. In: Koopman WJ, editors. Arthritis and allied conditions. Baltimore (MD): Williams and Wilkins;1997. p. 1923-42.
28. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53:1258-67.
29. Klein JP, Moeschberger ML. Survival analysis: Techniques for censored and truncated data. NewYork:SPringer-Verlag;1997.
30. Allison JP. Survival analysis using the SAS system. Cary NC:SAS Publishing;2001.
31. Practice Management Information Corporation. International Classification of Diseases, 9th Revision, Clinical Modification ICD-9-CM. Los Angeles CA:PRactice Management Information Corporation; 2001.
32. Zavras A, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis? J Oral Maxillofac Surg 2006;62:527-34.
33. Hitti M. FDA OKs first IV osteoporosis drug: Intravenous Boniva is now alternative to pill form. WebMD Medical News 2006 Jan 13. Available at: http://www.webmd.com/content/article/117/112556. [Last accessed: June 19, 2006.]
34. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006;11:1121-31.
35. Novartis Pharmaceuticals Corporation. Aredia. In: 2006 physicians desk reference. Montval (NJ):THompson PDR;2006. p. 2168-73.